Jennifer Boggs

Atlanta

Assistant Managing Editor at BioWorld

Assistant Managing Editor at BioWorld MedTech

Featured in: Favicon

bioworld.com Favicon

jamanetwork.com Favicon

realsimple.com Favicon

acpjournals.org Favicon

healio.com Favicon

jpeds.com

Articles

Celldex’s urticaria candidate impresses in post-treatment findings

2 weeks ago | bioworld.com | Jennifer Boggs

Celldex’s urticaria candidate impresses in post-treatment findingsCelldex Inc.’s KIT inhibitor, barzolvolimab, which hit its phase II endpoints in late 2023, kicking off phase III development in chronic spontaneous urticaria, offered up some impressive long-term findings at the EAACI Congress 2025, including complete responses in patients for as long as seven months after the cessation of therapy, which analysts said could position the drug as a potentially best-in-class option.
Philochem, BMS ink $1.35B deal for prostate cancer candidate OncoACp3

2 weeks ago | bioworld.com | Jennifer Boggs

Philochem, BMS ink $1.35B deal for prostate cancer candidate OncoACp3Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc. exclusive worldwide rights to OncoACP3, a diagnostic and therapeutic candidate targeting prostate cancer. BioWorld Deals and M&A Cancer Small molecule Diagnostics Europe U.S.
Metsera’s long-acting amylin analogue delivers in phase I

2 weeks ago | bioworld.com | Jennifer Boggs

Metsera’s long-acting amylin analogue delivers in phase I One of the big questions going into the phase I readout for Metsera Inc.’s amylin analogue, MET-233i, was whether findings would support once-monthly dosing for the potential obesity candidate. They did. Results also indicated solid and dose-dependent weight loss activity, and Metsera was able to identify well-tolerated starting doses for subsequent studies, said Steve Marso, chief medical officer.
Kymera’s phase I data lead big week for STAT6 space

3 weeks ago | bioworld.com | Jennifer Boggs

Kymera’s phase I data lead big week for STAT6 spaceIt’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic, surpassed expectations with impressive safety, pharmacokinetic and biomarker data from a phase I trial, while potential fast-followers from Nurix Therapeutics Inc. and Recludix Pharma Inc. advanced via respective partnerships with Sanofi SA.
Redemption for Lyra as second phase III rhinosinusitis trial hits goal

3 weeks ago | bioworld.com | Jennifer Boggs

Redemption for Lyra as second phase III rhinosinusitis trial hits goalShares of Lyra Therapeutics Inc. soared more than 310% on data from its second phase III trial testing drug-device candidate LYR-210 in patients with chronic rhinosinusitis, with results from the Enlighten 2 study showing statistical significance on primary and key secondary endpoints and offering hopes of a regulatory pathway ahead. BioWorld BioWorld MedTech Clinical Inflammatory Small molecule Combination drug-device U.S.
Consistency not enough? Summit falls on lung cancer survival miss

4 weeks ago | bioworld.com | Jennifer Boggs

Consistency not enough? Summit falls on lung cancer survival missFor the second time in as many months, the lack of statistically significant overall survival data sent shares of Summit Therapeutics Inc. sliding, despite otherwise positive findings for PD-1/VEGF bispecific candidate ivonescimab in non-small-cell lung cancer.
HHS terminating Moderna’s $590M grant for flu vaccines

1 month ago | bioworld.com | Jennifer Boggs

HHS terminating Moderna’s $590M grant for flu vaccinesThe funding boost Moderna Inc. had expected via a roughly $590 million Biomedical Advanced Research and Development Authority award now looks to be off the table. The company disclosed May 28 that the U.S. Department of Health and Human Services (HHS) said it will terminate the award for late-stage development and right to purchase pre-pandemic influenza vaccines. BioWorld Regulatory Infection Vaccine U.S. Policy
Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyout

1 month ago | bioworld.com | Jennifer Boggs

Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyoutFour months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via a buyout of Siteone Therapeutics Inc., a privately held firm developing small-molecule sodium channel inhibitors, including a phase II-ready NaV1.8 inhibitor. BioWorld Deals and M&A Neurology/psychiatric Small molecule U.S.
Apnimed’s oral sleep apnea candidate hits phase III endpoints

1 month ago | bioworld.com | Jennifer Boggs

Apnimed’s oral sleep apnea candidate hits phase III endpointsMirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy in obstructive sleep apnea hit primary and secondary endpoints. Should similar findings emerge from a second phase III trial, expected to read out in a couple of months, the privately held firm anticipates a U.S. NDA filing in early 2026. BioWorld BioWorld MedTech Clinical Neurology/psychiatric Small molecule U.S.
Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy

1 month ago | bioworld.com | Jennifer Boggs

Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buyIt’s been a big week for Inozyme Pharma Inc. On the heels of a promising interim readout for phase III-stage enzyme replacement therapy (ERT) candidate INZ-701 in ENPP1 deficiency, the firm agreed to be acquired by Biomarin Pharmaceuticals Inc. in a deal valued at about $270 million, putting the rare disease ERT in the hands of an experienced commercial team. BioWorld Deals and M&A Endocrine/metabolic Enzyme U.S.